Skip to main content
Fig. 5 | Journal of Nanobiotechnology

Fig. 5

From: Surface-anchored microbial enzyme-responsive solid lipid nanoparticles enabling colonic budesonide release for ulcerative colitis treatment

Fig. 5

Therapeutic efficacy of SLN-BUD-2L in a DSS-induced mouse model. (A) Establishment of DSS-induced colitis in mice and treatment regimens. (B) Mouse body weight changes, (C) fecal occult blood score, and (D) stool consistency score changes of each group for 12 days. (E) Scoring system for calculating the DAI based on weight loss, stool consistency and the degree of intestinal bleeding. (F) DAI score changes in each group for 12 days. (G) Colon photographs and (H) the length of colonic tissues isolated from mice after 5 days of treatment. (I) Spleen photographs and (J) spleen weight for each group. All data are expressed as the means ± SDs (n = 6; *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001)

Back to article page

Journal of Nanobiotechnology

ISSN: 1477-3155

Contact us